Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials

Basit Öğe Kaydı
dc.contributor.authorErgun, Y.
dc.contributor.authorKalkan, Z.
dc.contributor.authorIleri, S.
dc.contributor.authorTunc, S.
dc.contributor.authorUrakci, Z.
dc.date.accessioned2024-04-24T16:10:49Z
dc.date.available2024-04-24T16:10:49Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.descriptionEuropean-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress -- MAY 03-05, 2022 -- Berlin, GERMANYen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipEuropean Soc Med Oncolen_US
dc.identifier.doi10.1016/j.annonc.2022.03.203
dc.identifier.endpageS212en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.startpageS212en_US
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.03.203
dc.identifier.urihttps://hdl.handle.net/11468/15131
dc.identifier.volume33en_US
dc.identifier.wosWOS:000792494100187
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keyword]en_US
dc.titleEfficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trialsen_US
dc.titleEfficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu